Clinical Trials

Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

NCT04076059 2026-04-17

China ARCHES

180 enrolled 24 charts

Metastatic Hormone Sensitive Prostate Cancer

NCT02489318 2026-04-13

TITAN

1,052 enrolled 13 charts 1 FDA

Prostatic Neoplasms

NCT03767244 2026-04-13

PROTEUS

2,517 enrolled

Phase 4 Active not recruiting

Prostatic Neoplasms

NCT04108208 2026-04-13

A Study of Apalutamide in Chinese Participants With Non Metastatic Castration Resistant Prostate Cancer (NM-CRPC)

75 enrolled 9 charts

Prostatic Neoplasms

NCT04191096 2026-03-20

KEYNOTE-991

1,251 enrolled 15 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body

NCT05884398 2026-03-12

LIBERTAS

420 enrolled

Metastatic Castrate-sensitive Prostate Cancer

NCT04736199 2026-02-27

ARANOTE

669 enrolled 16 charts

Prostatic Neoplasms

NCT04034095 2025-12-15

A Registry Study to Observe Clinical Outcomes of Participants With High-risk Metastatic Hormone-naïve Prostate Cancer in Japan

Completed

979 enrolled

Prostatic Neoplasms

NCT03523338 2025-12-10

An Expanded Access Protocol for Apalutamide Treatment of Participants With Non-Metastatic Castration-Resistant Prostate Cancer

No longer available

Prostatic Neoplasms

NCT02799602 2025-12-04

ARASENS

1,306 enrolled 25 charts 4 FDA

Metastatic Hormone-sensitive Prostate Cancer

NCT04934722 2025-10-01

KEYNOTE-991

186 enrolled 14 charts

Parkinson Disease 4, Autosomal Dominant Lewy Body

NCT05171387 2025-06-22

Darolutamide + Androgen Deprivation Therapy (ADT) in Chinese Men With High Risk, Nonmetastatic Prostate Cancer

Phase 2 Completed

78 enrolled

Phase 2 Not yet recruiting

Prostatic Neoplasms

NCT06765954 2025-05-06

Immunotherapy With N 803, ETBX-071, and M-CENK in Combination With Radiation for Participants With High-Risk Prostate Cancer.

20 enrolled

Prostatic Neoplasms

NCT03641560 2025-04-08

A Safety and Efficacy Study of Enzalutamide in Indian Patients With Progressive Metastatic Castration-Resistant Prostate Cancer (mCRPC) Previously Treated With Docetaxel-Based Chemotherapy

Phase 4 Completed

52 enrolled 10 charts

Phase 1/2 Active not recruiting

Metastatic Castration Resistant Prostate Cancer

NCT05067140 2025-03-17

A Study of ARV-766 Given by Mouth in Men With Metastatic Prostate Cancer

152 enrolled

Genital Neoplasms, Male, Prostatic Neoplasms, Urogenital Neoplasms

NCT01715285 2025-02-04

A Study of Abiraterone Acetate Plus Low-Dose Prednisone Plus Androgen Deprivation Therapy (ADT) Versus ADT Alone in Newly Diagnosed Participants With High-Risk, Metastatic Hormone-Naive Prostate Cancer (mHNPC)

1,209 enrolled 16 charts 1 FDA

Prostatic Neoplasms

NCT02918968 2024-12-09

Study on Enzalutamide and Flutamide in Patients With Castration Resistant Prostate Cancer

Phase 4 Completed

206 enrolled 16 charts

Prostatic Neoplasms

NCT06498921 2024-10-24

BELBEQA

Completed

106 enrolled

Metastatic Hormone-sensitive Prostate Cancer

NCT05149131 2024-02-09

A Study Called AWARENESS Using Data From Men in Alberta to Observe Treatment Patterns for Metastatic Castration-sensitive Prostate Cancer

Completed

960 enrolled

Metastatic Castration-sensitive Prostate Cancer

NCT02217566 2020-01-13

Study of Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC), Chemo-Naive, Who Received a Prior Diethylstilbestrol Therapy

Phase 2 Completed

46 enrolled 13 charts

Prostatic Neoplasms

NCT00242567 2014-05-07

Study of Zoledronic Acid for Patients With Hormone-sensitive Bone Metastases From Prostate Cancer

522 enrolled 8 charts